Anzeige
Mehr »
Login
Mittwoch, 23.09.2020 Börsentäglich über 12.000 News von 645 internationalen Medien
GOLDPREIS-KORREKTUR zur richtigen Zeit! Diese Firma profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
18:08Sun Pharma the latest to recall metformin after carcinogen tests come up positive
18:08ICER rubber-stamps Vertex's $311K CF drug Trikafta but blasts 'monopoly' pricing
17:08Fujifilm's flu drug Avigan improves COVID-19 recovery time, setting up filing in Japan
16:42Humanigen, Thermo Fisher strike deal to scale up manufacturing of monoclonal antibody for COVID-19
16:42Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve
DiBristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
DiHow will BMS' new Opdivo-Cabometyx kidney cancer combo fare against Keytruda? It may come down to marketing: analyst
DiFormer Biogen CFO Capello scores $2.6M payment plus full severance benefits on his way out
DiPharma TV spending bounced back with pro sports in August, with AbbVie, Regeneron/Sanofi leading the way
DiAstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push
DiViral vector manufacturer Vibalogics adds CEO to lead expansion, COVID-19 response
MoESMO: Merck's Keytruda pushes for second esophageal cancer nod with first-line survival win
MoESMO: Bristol Myers' Opdivo racks up GI cancer data for two potentially practice-changing FDA nods
MoChinese customs raids J&J CAR-T partner Legend's office, puts new CEO under 'residential surveillance'
MoFiercePharmaPolitics-White House, pharma pricing talks fell apart over demand for 'Trump Cards': NYT
MoESMO: Merck's Keytruda doubles 5-year survival rate for lung cancer patients
SoESMO: AstraZeneca, Merck's Lynparza boosts prostate cancer survival by 31% over J&J, Pfizer-Astellas rivals
SoESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show
SaESMO: Bristol Myers preps 2nd kidney cancer combo nod as Opdivo-Cabometyx duo slashes death risk 40%
SaESMO: New Trodelvy breast, bladder cancer data show why Gilead's going big for Immunomedics
SaESMO: Merck's Keytruda matches Opdivo on key survival metric for post-surgery melanoma
SaESMO: Pfizer's Ibrance flop in early breast cancer shouldn't hurt metastatic sales, exec says
SaESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial
FrAstellas, Seattle Genetics' Padcev bladder cancer trial stops early with 30% death risk reduction
FrBiogen stands to lose billions in Tecfidera sales next year, analyst says after new court ruling